FDA Drug recall D-0339-2019
Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle, Rx Only,Distributed by Pfizer Inc
- FDA Drug
- Class II
- terminated
- Published 2018-12-26
On 2018-12-26 the FDA classified a Class II recall of Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle, Rx Only,Distributed by Pfizer Inc by Pfizer, citing superpotent Drug.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0339-2019 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2018-12-06 |
| Published | 2018-12-26 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Pfizer |
| Distribution | US |
Product
Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle, Rx Only,Distributed by Pfizer Inc. New York, NY 10017, NDC 60793-855-01
Reason
Superpotent Drug.
Identifiers
| ndc | 60793-850-10 |
|---|---|
| ndc | 60793-850-01 |
| ndc | 60793-851-10 |
| ndc | 60793-851-01 |
| ndc | 60793-852-10 |
| ndc | 60793-852-01 |
| ndc | 60793-853-10 |
| ndc | 60793-853-01 |
| ndc | 60793-854-10 |
| ndc | 60793-854-01 |
| ndc | 60793-855-10 |
| ndc | 60793-855-01 |
| ndc | 60793-856-10 |
| ndc | 60793-856-01 |
| ndc | 60793-857-10 |
| ndc | 60793-857-01 |
| ndc | 60793-858-10 |
| ndc | 60793-858-01 |
| ndc | 60793-859-10 |
| ndc | 60793-859-01 |
| ndc | 60793-860-10 |
| ndc | 60793-860-01 |
| code_info | Lot #:18A18, Exp. 01/2020 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0339-2019%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.